



HAL
open science

Linking anemia to inflammation and cancer: the crucial role of $\text{TNF}\alpha$

Isabelle Buck, Franck Morceau, Christina Grigorakaki, Mario Dicato, Marc Diederich

► To cite this version:

Isabelle Buck, Franck Morceau, Christina Grigorakaki, Mario Dicato, Marc Diederich. Linking anemia to inflammation and cancer: the crucial role of $\text{TNF}\alpha$. *Biochemical Pharmacology*, 2009, 77 (10), pp.1572. 10.1016/j.bcp.2008.12.018 . hal-00493483

HAL Id: hal-00493483

<https://hal.science/hal-00493483>

Submitted on 19 Jun 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Linking anemia to inflammation and cancer: the crucial role of TNF α

Authors: Isabelle Buck, Franck Morceau, Christina Grigorakaki, Mario Dicato, Marc Diederich



PII: S0006-2952(08)00902-7
DOI: doi:10.1016/j.bcp.2008.12.018
Reference: BCP 10047

To appear in: *BCP*

Received date: 6-10-2008
Revised date: 3-12-2008
Accepted date: 16-12-2008

Please cite this article as: Buck I, Morceau F, Grigorakaki C, Dicato M, Diederich M, Linking anemia to inflammation and cancer: the crucial role of TNF α , *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2008.12.018

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Linking anemia to inflammation and cancer: the crucial role of TNF α .**Isabelle Buck, Franck Morceau, Christina Grigorakaki, Mario Dicato and Marc Diederich***

Laboratoire de Biologie Moléculaire et Cellulaire du Cancer (LBMCC), Fondation Recherche Cancer et Sang, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540 Luxembourg

***Corresponding author.** Tel.: +352 2468-4040; fax: +352 2468-4060.

E-mail: marc.diederich@lbmcc.lu (M. Diederich)

Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg.

Classification: 6. Molecular Pharmacology

Abbreviations: Epo, Erythropoietin; NF- κ B, Nuclear Factor-kappa B; FOG-1, Friend of GATA; NF-E2, nuclear factor erythroid 2; EKLF, erythroid krüppel like factor; SCF, stem cell factor; EpoR, Epo receptor; HIF, hypoxia inducible factor; HSC, hematopoietic stem cell factor; BFU-E, burst forming unit erythroid; CFU-E colony forming unit erythroid; FA, Fanconi anemia; GPA, glycophorin A; TNF α , Tumor Necrosis Factor alpha; TNFR, TNF α receptor; ESA, erythroid stimulating agent.

Abstract

Erythropoiesis is considered as a multistep and tightly regulated process under the control of a series of cytokines including erythropoietin (Epo). Epo activates specific signaling pathways and leads to activation of key transcription factors such as GATA-1, in order to ensure erythroid differentiation. Deregulation leads to a decreased number of red blood cells, a hemoglobin deficiency, thus a limited oxygen-carrying capacity in the blood. Anemia represents a frequent complication in various diseases such as cancer or inflammatory diseases. It reduces both quality of life and prognosis in patients. Tumor necrosis factor alpha (TNF α) was described to be involved in the pathogenesis of inflammation and cancer related anemia. Blood transfusions and erythroid stimulating agents (ESAs) including human recombinant Epo (rhuEpo) are currently used as efficient treatments. Moreover, the recently described conflicting effects of ESAs in distinct studies require further investigations on the molecular mechanisms involved in TNF α -caused anemia. The present study aims to evaluate the current knowledge and the importance of the effect of the proinflammatory cytokine TNF α on erythropoiesis in inflammatory and malignant conditions.

Key words

TNF α , Erythropoietin, erythroid differentiation, inflammation, cancer

1. Introduction

The proinflammatory cytokine tumor necrosis factor (TNF α) was brought in connection with inflammation and cancer, two tightly linked research areas [1-3] and it was demonstrated that cancer-associated inflammation could promote tumor growth [1, 4, 5]. TNF α expression has been confirmed in the tumor microenvironment of various malignancies [6] and was categorized as a tumor promoter because of its effects on tumor initiation and progression [7, 8]. Furthermore there are more and more drugs in clinical development that modulate TNF α function in a wide range of inflammatory diseases and cancers [8].

Cancer and inflammation related anemia were shown to be mediated by cytokine release, and particularly by TNF α , Interferon- β (IFN- β), and Interleukin-1 (IL-1) [9]. Moreover, inhibition of colony-forming units-erythroid (CFU-E) in uremic patients with inflammatory disease due to TNF α and IFN- γ release has been reported [10]. Following anti-TNF α therapy, patients with rheumatoid arthritis showed improvement in anemic symptoms [11]. Since several years, human recombinant erythropoietin (rhuEpo) is a specific remedy administered against cancer-associated anemia. This treatment has a positive impact on hemoglobin levels and patient quality of life is improved. However, a preclinical background and some clinical data suggest a detrimental role of Epo in cancer by a possible stimulation of tumor growth.

2. Regulation of erythropoiesis

Hematopoiesis is the physiological process that leads to the formation of circulating blood cells from common hematopoietic stem cells (HSC) in the bone marrow. The different mature hematopoietic cells are usually classified in lymphoid and myeloid lineages. They are regulated by distinct cytokines acting on multipotential progenitors and their committed offspring [12, 13] (Fig. 1).

Erythropoiesis is a multistep event leading to the formation of erythrocytes. Erythroid differentiation arises from the myeloid root and is phenotypically characterized by the production of hemoglobin and expression of erythroid markers (Fig. 2). During differentiation from a multipotent common myeloid progenitor (CMP) to a bipotent megakaryocytic/erythroid progenitor (MEP), burst-forming units erythroid (BFU-E)

and CFU-E are the earliest identifiable erythroid progenitors in culture (Fig. 1). BFU-E and CFU-E are characterized by their *in vitro* ability to form colonies.

Erythropoiesis is a very dynamic and tightly regulated process by which 2×10^{11} erythrocytes (lifespan of 100-120 days) are produced every day. Ferrous iron (Fe^{2+}) is essential for erythropoiesis as a major component of heme in hemoglobin as well as in the redox system of the respiratory chain. Hepcidin, a 25-amino acid peptide, is the main regulator of iron transport. A feedback loop involving the major cytokine for human erythropoiesis, Epo, regulates this physiological process, but other cytokines and nuclear hormones are also involved. IL-3 increases the number of BFU-E, whereas Stem Cell Factor (SCF) raises the number of cells within BFU-E and CFU-E (Fig. 1).

Kidney and liver are the main sites that produce the Epo in adult humans. The rate of Epo gene expression depends on the level of tissue oxygen through the availability of the hypoxia inducible factor (HIF). HIF heterodimer is composed of the oxygen sensitive HIF-1 α and the constitutively expressed HIF-1 β subunits. In hypoxic conditions HIF interacts with specific binding sites in the Epo enhancer. Oxygen-dependent prolyl hydroxylases control Epo variations in the kidney by regulating the stability of HIF-1 α . The number of circulating erythrocytes is directly dependent on Epo amount in blood.

Epo is implicated in the control of cell survival, proliferation and differentiation within the erythroid pathway. It acts through its receptor (EpoR) in order to stimulate underlying cell signaling pathways including the Phosphatidylinositol 3 kinase (PI3K), the Janus kinase (JNK)/Signal-transducer and activator of transcription (STAT) and the mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase pathways (ERK) [14]. Moreover, Epo has been reported to modulate GATA-1 function in erythroid cells [15].

The survival of erythroid precursors and their terminal differentiation into red blood cells depends on Epo/EpoR interaction and GATA-1 transcription factor activity. GATA-1 was first identified as a protein with binding capacity to the β -globin promoter [16]. It is a member of the GATA family, which includes 6 members (GATA-1 to GATA-6). These transcription factors recognize the same DNA consensus sequence (A/T)GATA(A/G) and present two characteristic zinc finger motifs specific to the GATA family [17]. Three functional domains compose GATA-

1 protein: the N-terminal Zinc finger that supplies the stabilization and specificity of DNA binding and is responsible for the interactions with cofactors, the C-terminal Zinc finger that is essential for binding to the GATA consensus sequence of the DNA and the N-terminal activation domain [18].

GATA-1 is required for terminal erythroid maturation [19]. Indeed, its crucial role in erythropoiesis was shown using GATA-1 null mouse embryos, which died between E10.5 and E12.5 from severe anemia due to a complete ablation of embryonic erythropoiesis [20]. Moreover, GATA-1^{-/-} embryonic stem cells cannot contribute to definitive erythropoiesis [21].

GATA-1 activity is dependent on protein-protein interactions, involving cofactors with either promoting or repressing activities [18] (Table 1). The transcription factor PU.1, an Ets family member of transcription factors, is required for the development of the myeloid and lymphoid lineages. Nevertheless, its inhibitory effect on GATA-1 activity can prevent erythroid differentiation. PU.1 and GATA-1 have a cross-antagonistic relationship. Indeed, GATA-1 and PU.1 seem to functionally antagonize each other via direct physical interaction of their DNA-binding domains. PU.1 impairs GATA-1 by inhibiting its binding to DNA while GATA-1 inhibits PU.1 by preventing its interaction with c-Jun [22].

In summary, GATA-1 activity is dependent on complex positive and negative interactions with transcriptional cofactors as well as posttranslational modifications leading to modulation of erythroid lineage-specific genes transcription.

GATA-2, Nuclear Factor Erythroid-2 (NF-E2) and erythroid Krüppel-like factor (EKLF) are other specific transcription factors that have a major influence on erythroid differentiation and that are activated during erythropoiesis. GATA-2 is overexpressed during early hematopoiesis resulting in maintenance of the renewal capacity of erythroid progenitor cells. Its expression is then progressively repressed by the increasing expression of GATA-1 [23]. NF-E2, is described to act as a major regulator of hemoglobin synthesis during erythropoiesis [24], and EKLF, as a crucial factor in erythroid and megakaryocytic differentiation and maturation [25, 26] (Table 1).

Deregulation of Epo or other key factors of erythroid differentiation can lead to major changes in red blood cell number, and subsequent decrease in the oxygen-carrying capacity of the blood. Erythrocytosis are disorders resulting in an excessively high

level of erythrocytes, whereas anemia is characterized by a qualitative or quantitative deficiency of hemoglobin. Anemia is clinically defined by a hemoglobin (Hb) level inferior to 12g/dL.

3. Tumor necrosis factor alpha

TNF α also known as cachectin or differentiation inducing factor (DIF), is a proinflammatory multifunctional cytokine, which is mainly produced by macrophages, but also by neutrophils, fibroblasts, keratinocytes, astrocytes, Kupffer cells, smooth-muscle cells, T and B cells. It was initially described to induce hemorrhagic necrosis in transplanted tumors [27]. TNF α effects are principally mediated through two distinct receptors TNF α receptor (TNFR) I and II. TNF α /TNFR interaction results in stimulation of the underlying cell signaling pathways that lead to nuclear factor kappa B (NF- κ B), c-Jun N-terminal kinase (JNK), p38MAPK, or caspase activation. Thus TNF α simultaneously activates both apoptotic and anti-apoptotic or cell survival signals depending on the factors present in the receptor complex [28]. TNF α , which was discovered in B cells, is known as the most powerful activator of NF- κ B transcription factor. NF- κ B is known to bind its specific ten base pair consensus-binding site in order to regulate over 200 immune, growth, and inflammation genes.

TNF α , as well as other TNF α superfamily members, plays a role in hematopoiesis, host defense, immune surveillance, and proliferation. In this regard, TNF α deregulation leads to numerous diseases, including cancer [28-30].

4. TNF α and inflammation

A TNF α overproduction is involved in numerous chronic inflammatory diseases, such as rheumatoid arthritis [31] chronic hepatitis C [32], or Crohn's disease [33]. An increase in the TNF α level was described in diabetic patients to cause retinopathies [34], while during pancreatitis, the release of TNF α leads to inflammation and cellular damage [35].

Currently, three marketed TNF α antagonists [etanercept (Enbrel®), infliximab (Remicade®), and adalimumab (Humira®)] are indicated in diseases characterized by

abnormally elevated TNF α levels. Moreover the effectiveness of the treatments varies with agent and disease [36, 37]. TNF α is thus leading to various biological phenomena implying different molecular mechanisms and is involved in different cellular responses. Although TNF α is considered to act as a proinflammatory cytokine, it was described as a positive and negative regulator of myeloid cell proliferation and differentiation [38-40]. Effects of TNF α can be mediated either directly [41] or indirectly by inducing other cells to produce cytokines, including hematopoietic growth factors [42, 43].

5. Link between TNF α , inflammation and cancer

Abnormal TNF α levels have been confirmed in tumor microenvironment [6]. Moreover, this cytokine is paradoxically able to induce necrosis and to promote tumor development, depending on the levels of TNF α in distinct settings [44]. When TNF α is secreted by tumors and tumor-associated macrophages, it promotes tumor growth and stimulates angiogenesis, whereas when it is administered therapeutically at high doses, it induces an increased permeability of tumor vasculature. Thus, recombinant TNF α , as a tumor regressing agent, is approved in Europe to be administered locoregionally at supraphysiological levels as a therapy for soft tissue sarcoma [45].

Using murine models, it was shown that inflammation-associated hepatocellular carcinogenesis involved the activation of the tumor promoter NF- κ B via the production of TNF α [5]. Moreover several reports associate detection of abnormally high levels of TNF α protein and/or constitutively active NF- κ B in cancer patients with a wide range of tumor types [46], including kidney [47], breast [48], asbestosis induced lung [49], and prostate cancers [50]. Suppression of constitutively active NF- κ B results in cell proliferation arrest and apoptosis, indicating a crucial role for NF- κ B in proliferation and survival [51]. Furthermore chronic bioavailability of TNF α has been correlated with enhanced invasive activities as well as survival of neoplastic cells [44]. Within groups of patients with the same tumor type, higher levels of TNF α have been correlated with advanced tumor stage, greater complications, and shorter survival time [52]. Moreover various cytokines, including TNF α , are overexpressed in pancreatic cancer cells, leading to an NF- κ B activation and as a consequence, to

cell growth by inhibiting apoptosis [53]. TNF α also appears as a growth factor regulated by NF- κ B in Hodgkin's lymphoma, T cell lymphoma and glioma [54].

As Rudolf Virchow already suspected in 1863, inflammation and cancer have to be handled together [1, 3]. Cancer-associated inflammation includes the expression of cytokines such as TNF α or IL-1 by tumor-associated macrophages, stimulating tumor growth [55]. As TNF α was categorized as a tumor promoter, it is not astonishing that cytokine antagonists as well as NF- κ B inhibitors are already used in cancer therapy and prevention [7, 8, 44].

6. Deregulation of erythropoiesis by TNF α in inflammation and cancer.

Besides the proinflammatory, proliferative and apoptotic properties, TNF α was also described as an inhibitor of the erythroid differentiation *in vitro* and *in vivo* [38, 39, 41, 56] (Fig. 3). Its expression is associated with the hematologic diseases Fanconi anemia (FA) [57], myelodysplastic syndromes [58], aplastic anemia [59] and anemia due to chronic diseases [60]. Indeed, in FA patients, TNF α is significantly overexpressed in stimulated marrow mononuclear cells, which leads to a suppression of erythropoiesis. In bone marrow cultures, the addition of anti-TNF α increases the size and the number of CFU-E and BFU-E grown from FA patients but not from healthy controls. This indicates that FA subjects have a marrow TNF α activity that inhibits erythropoiesis *in vitro*. TNF α plays a relevant role in the pathogenesis of erythroid failure in FA patients [57]. Several *in vitro* studies revealed the inhibitory effects of this cytokine on hematopoietic progenitor cell growth [38, 39, 41, 56, 57, 61]. It was shown that the inhibition of human CFU-E by TNF α requires IFN- β , which is produced by macrophages in response to TNF α . TNF α was also shown to have a direct inhibitory effect on Epo-induced generation of GPA positive cells from CD34+ progenitors, leading to the suppression of erythropoiesis and the reduction of the proliferation capacity of GPA positive cells [61]. Interestingly, TNF α is also believed to play a critical role in many forms of cancer [9, 62] and inflammation related anemia [11]. Indeed anemia is considered as a common symptom induced by inflammation and cancer pathologies. In patients with B-cell chronic lymphocytic leukemia suffering from anemia, the serum levels of TNF α were significantly higher than in those without anemia [63]. The incidence of anemia was shown to vary with

tumor type, stage and patient age. Up to one third of patients had anemia at diagnosis [64]. This number increases after chemotherapy [65]. Cancer-associated anemia was shown to reduce survival of patients regardless of tumor type [66]. Moreover, the quality of life is considerably affected and is associated with a range of symptoms including fatigue, depression, and dizziness [67]; thus pro-inflammatory cytokines were recently suggested as the common denominator for cancer related fatigue [68]. Inflammation associated anemia is considered as a main symptom of patients with inflammatory disorders [69]. Prior to the use of erythroid stimulating agents (ESAs), the most frequent treatment of cancer related anemia was blood transfusion. Clinical trials established erythropoietin's ability to increase hemoglobin levels and reduce transfusion requirements [2, 3]. However, the conflicting effects of ESAs were recently described in distinct studies [70-72]. Indeed, besides cardiovascular and thromboembolic events in erythropoietin-treated patients, several phase II and III trials showed a significant deterioration of cancer patients survival [73-75]. Unexpectedly, the increased mortality came from accelerated progression of cancer. This reproducible effect was attributed to erythropoietin. Thus, the use of erythropoietin in cancer patients might increase the risk of cancer-associated death. It is suggested that additional phase III trials should be performed to determine whether erythropoietin is safe when used in accordance with FDA-approved indications. One claims that waiting for these further studies to modify or stop Epo treatments could have detrimental impact on many cancer patients [70]. In this context, controversial effects of erythropoietin in cancer-related anemia makes necessary to further investigate the molecular mechanisms involved in anemia and to identify new targets for drug development as well as to detect more significant predictors. In order to improve quality of life, several drugs are under investigation for the treatment of different forms of anemia. Jelkmann reviewed several anti-anemic drugs and techniques based on Epo gene expression [71, 76].

Additionally, our group previously reported that TNF α -mediated inhibition of K562 cell differentiation was correlated to GATA-1 downregulation [77], GATA-1/GATA-2 unbalance in favor of GATA-2 as well as a decrease in the acetylation status of GATA-1 [78, 79]. Moreover we suggested a role for p38 in the inhibition of erythroid differentiation by TNF α , in correlation with a reversal of important erythroid transcription factors [78]. Miwatashi and colleagues already used a novel p38

inhibitor, N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl] benzamide (TAK-715), as an anti-TNF α drug for the treatment of rheumatoid arthritis, presenting anemic complications [11, 80].

7. Conclusions

Erythropoiesis is a tightly regulated, complex physiological process leading to the formation of erythrocytes from a pluripotent hematopoietic stem cell. Deregulation can lead to various complications, including anemia. Anemia represents a frequent complication in cancer patients, as well as in patients suffering from inflammatory diseases. Proinflammatory cytokines seem to be overexpressed in these diseases. Anemia considerably affects quality of life and is even considered as an independent bad prognostic factor. On the other hand some studies showed that the use of recombinant Epo as a treatment for cancer related anemia could be inappropriate for cancer patients. For these reasons the molecular mechanisms behind the inhibitory effect of TNF α on erythroid differentiation need to be further elucidated in order to find potential new, and more pointed therapeutic targets for inflammation and cancer related anemia. In this respect, investigations using hematopoietic stem cell culture systems should allow to better understand the impact of TNF α on the control of erythropoiesis by identifying which specific cellular process is affected, including differentiation and/or apoptosis regulation.

Acknowledgements

Research in MD's lab is supported by the 'Recherche Cancer et Sang' foundation, the 'Recherches Scientifiques Luxembourg' association, Télévie and Action Lions Vaincre le Cancer. I.B. is supported by 'Action Lions Vaincre le Cancer' and C.G. by an AFR grant from FNR Luxembourg. The authors thank M. Groos for collaboration and 'Een Häerz fir kriibskrank Kanner' association for continuous support.

Legends to figures

Figure 1: Hematopoiesis and the role of cytokines. Cytokines act both on multipotential progenitors and their committed offspring. CLP, common lymphoid progenitor; CMP, common myeloid progenitor; HSC, hematopoietic stem cell; GMP, granulocyte–macrophage progenitor; MEP, megakaryocyte erythroid progenitor; BFU-E, burst-forming units-erythroid; CFU-E, colony-forming units-erythroid; CFU-Meg, colony-forming units-megakaryocyte; MPP, multipotent progenitor; IL, Interleukin; SCF, stem cell factor; GM-CSF, granulocyte-macrophage colony stimulating factor; G-CSF, granulocyte colony stimulating factor; M-CSF, macrophage colony stimulating factor; TPO, thrombopoietin; Epo, Erythropoietin (Adapted from [12, 13] with modifications).

Figure 2: Stages of mammalian erythropoiesis and corresponding expression of erythroid specific markers. The relative sizes and morphologic appearances of erythroid cells at various stages of differentiation: common myeloid progenitor (CMP), megakaryocyte erythroid progenitor (MEP), burst-forming units-erythroid (BFU-E), colony-forming units-erythroid (CFU-E), proerythroblasts (Pro EB), basophilic erythroblasts (Baso EB), polychromatophilic erythroblasts (Poly EB), orthochromatic erythroblasts (Ortho EB), reticulocytes (RET), and erythrocytes (Eryt). Erythroid markers are represented in red and their periods of expression with gray lines: erythropoietin receptor (EpoR), Glycophorin A (GPA), Transferrin receptors (TFRC), δ -aminolevulinate synthase (δ -ALA-S) (Adapted from [81]).

Figure 3: Pathophysiology of anemia. Tumor cells act on erythrocytes through macrophages by cytokine release, which leads to impaired erythropoiesis. Released cytokines can affect BFU-E and CFU-E proliferation, iron utilization and Epo production. $\text{TNF}\alpha$ can also affect erythrocyte half-life. $\text{TNF}\alpha$, tumor necrosis factor alpha; IFN, Interferon; IL, Interleukin; BFU-E, burst-forming units-erythroid; CFU-E, colony-forming units-erythroid; Epo, Erythropoietin (Adapted from [68]).

References

- [1] Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* 2005;7:211-7.
- [2] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001;357:539-45.
- [3] Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;420:860-7.
- [4] Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 2004;118:285-96.
- [5] Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature* 2004;431:461-6.
- [6] Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. *Lancet Oncol* 2003;4:565-73.
- [7] Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. *Eur J Cancer* 2006;42:745-50.
- [8] Yan L, Anderson GM, DeWitte M, Nakada MT. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. *Eur J Cancer* 2006;42:793-802.
- [9] Bokemeyer C, Oechsle K, Hartmann JT. Anaemia in cancer patients: pathophysiology, incidence and treatment. *Eur J Clin Invest* 2005;35 Suppl 3:26-31.
- [10] Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. *J Investig Med* 1999;47:204-11.
- [11] Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. *Blood* 2002;100:474-82.
- [12] Robb L. Cytokine receptors and hematopoietic differentiation. *Oncogene* 2007;26:6715-23.
- [13] Wickrema A, Crispino JD. Erythroid and megakaryocytic transformation. *Oncogene* 2007;26:6803-15.
- [14] Hodges VM, Rainey S, Lappin TR, Maxwell AP. Pathophysiology of anemia and erythrocytosis. *Crit Rev Oncol Hematol* 2007;64:139-58.
- [15] Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. *Blood* 2006;107:907-15.
- [16] Wall L, deBoer E, Grosveld F. The human beta-globin gene 3' enhancer contains multiple binding sites for an erythroid-specific protein. *Genes Dev* 1988;2:1089-100.
- [17] Merika M, Orkin SH. DNA-binding specificity of GATA family transcription factors. *Mol Cell Biol* 1993;13:3999-4010.
- [18] Morceau F, Schnekenburger M, Dicato M, Diederich M. GATA-1: friends, brothers, and coworkers. *Ann N Y Acad Sci* 2004;1030:537-54.

- [19] Ferreira R, Ohneda K, Yamamoto M, Philipsen S. GATA1 function, a paradigm for transcription factors in hematopoiesis. *Mol Cell Biol* 2005;25:1215-27.
- [20] Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. *Proc Natl Acad Sci U S A* 1996;93:12355-8.
- [21] Pevny L, Simon MC, Robertson E, Klein WH, Tsai SF, D'Agati V, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. *Nature* 1991;349:257-60.
- [22] Rekhtman N, Radparvar F, Evans T, Skoultschi AI. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. *Genes Dev* 1999;13:1398-411.
- [23] Grass JA, Boyer ME, Pal S, Wu J, Weiss MJ, Bresnick EH. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. *Proc Natl Acad Sci U S A* 2003;100:8811-6.
- [24] Andrews NC, Erdjument-Bromage H, Davidson MB, Tempst P, Orkin SH. Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. *Nature* 1993;362:722-8.
- [25] Lu SJ, Rowan S, Bani MR, Ben-David Y. Retroviral integration within the Fli-2 locus results in inactivation of the erythroid transcription factor NF-E2 in Friend erythroleukemias: evidence that NF-E2 is essential for globin expression. *Proc Natl Acad Sci U S A* 1994;91:8398-402.
- [26] Perkins AC, Peterson KR, Stamatoyannopoulos G, Witkowska HE, Orkin SH. Fetal expression of a human Agamma globin transgene rescues globin chain imbalance but not hemolysis in EKLf null mouse embryos. *Blood* 2000;95:1827-33.
- [27] Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci U S A* 1975;72:3666-70.
- [28] Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* 2003;3:745-56.
- [29] Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? *Biochem Pharmacol* 2006;72:1605-21.
- [30] Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. *Cytokine Growth Factor Rev* 2003;14:185-91.
- [31] Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. *Annu Rev Immunol* 1996;14:397-440.
- [32] Knobler H, Schattner A. TNF- α , chronic hepatitis C and diabetes: a novel triad. *Qjm* 2005;98:1-6.
- [33] Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med* 1997;337:1029-35.
- [34] Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular


- membranes of proliferative diabetic retinopathy. *Br J Ophthalmol* 1996;80:168-73.
- [35] Friess H, Guo XZ, Nan BC, Kleeff O, Buchler MW. Growth factors and cytokines in pancreatic carcinogenesis. *Ann N Y Acad Sci* 1999;880:110-21.
- [36] Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors. *J Rheumatol Suppl* 2005;74:3-7.
- [37] Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. *J Rheumatol Suppl* 2005;72:46-7.
- [38] Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. *J Immunol* 1986;136:4487-95.
- [39] Murase T, Hotta T, Saito H, Ohno R. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. *Blood* 1987;69:467-72.
- [40] Rusten LS, Smeland EB, Jacobsen FW, Lien E, Lesslauer W, Loetscher H, et al. Tumor necrosis factor-alpha inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors. *J Clin Invest* 1994;94:165-72.
- [41] Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. *Blood* 1995;85:989-96.
- [42] Means RT, Jr., Dessypris EN, Krantz SB. Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells. *J Clin Invest* 1990;86:538-41.
- [43] Means RT, Jr., Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. *J Clin Invest* 1993;91:416-9.
- [44] Balkwill F. Tumor necrosis factor or tumor promoting factor? *Cytokine Growth Factor Rev* 2002;13:135-41.
- [45] van Etten B, van Geel AN, de Wilt JH, Eggermont AM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. *Ann Surg Oncol* 2003;10:32-7.
- [46] Mantovani G, Maccio A, Mura L, Massa E, Mudu MC, Mulas C, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. *J Mol Med* 2000;78:554-61.
- [47] Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. *Br J Cancer* 2002;86:1396-400.
- [48] Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. *Br J Cancer* 1998;77:2246-51.
- [49] Partanen R, Koskinen H, Hemminki K. Tumour necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer. *Occup Environ Med* 1995;52:316-9.

- [50] Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Jr., Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. *Cancer* 2003;97:1211-6.
- [51] Aggarwal BB. Nuclear factor-kappaB: the enemy within. *Cancer Cell* 2004;6:203-8.
- [52] Bossola M, Muscaritoli M, Bellantone R, Pacelli F, Cascino A, Sgadari A, et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. *Eur J Clin Invest* 2000;30:1107-12.
- [53] Chang I, Kim S, Kim JY, Cho N, Kim YH, Kim HS, et al. Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis. *Diabetes* 2003;52:1169-75.
- [54] Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. *Oncogene* 1999;18:6853-66.
- [55] Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. *Crit Rev Oncol Hematol* 2008;66:1-9.
- [56] Roodman GD. Mechanisms of erythroid suppression in the anemia of chronic disease. *Blood Cells* 1987;13:171-84.
- [57] Dufour C, Corcione A, Svahn J, Haupt R, Poggi V, Beka'ssy AN, et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. *Blood* 2003;102:2053-9.
- [58] Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. *Br J Haematol* 1998;103:176-88.
- [59] Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. *Br J Haematol* 2001;115:1023-31.
- [60] Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, Kodama T, et al. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. *Faseb J* 2003;17:1742-4.
- [61] Xiao W, Koizumi K, Nishio M, Endo T, Osawa M, Fujimoto K, et al. Tumor necrosis factor-alpha inhibits generation of glycophorin A+ cells by CD34+ cells. *Exp Hematol* 2002;30:1238-47.
- [62] Kurzrock R. The role of cytokines in cancer-related fatigue. *Cancer* 2001;92:1684-8.
- [63] Capalbo S, Battista C, Delia M, Ciancio A, De Santis G, Dargenio M, et al. Evaluation of tumor necrosis factor-alpha and erythropoietin serum levels in B-cell chronic lymphocytic leukemia patients with anemia. *Acta Haematol* 2002;108:84-9.
- [64] Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. *Am J Med* 2004;116 Suppl 7A:11S-26S.
- [65] Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, et al. Anemia in oncology practice: relation to diseases and their therapies. *Am J Clin Oncol* 2002;25:371-9.

- [66] Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. *Cancer* 2001;91:2214-21.
- [67] Pronzato P. Cancer-related anaemia management in the 21st century. *Cancer Treat Rev* 2006;32 Suppl 2:S1-3.
- [68] Engert A. Recombinant human erythropoietin in oncology: current status and further developments. *Ann Oncol* 2005;16:1584-95.
- [69] Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. *J Clin Invest* 2004;113:1251-3.
- [70] Blau CA. Erythropoietin in cancer: presumption of innocence? *Stem Cells* 2007;25:2094-7.
- [71] Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. *Br J Haematol* 2008;141:287-97.
- [72] Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. *Blood* 2008;111:25-41.
- [73] Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. *Lancet* 2003;362:1255-60.
- [74] Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. *J Clin Oncol* 2005;23:5960-72.
- [75] Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. *J Clin Oncol* 2007;25:1027-32.
- [76] Jelkmann W. Control of erythropoietin gene expression and its use in medicine. *Methods Enzymol* 2007;435:179-97.
- [77] Morceau F, Schnekenburger M, Blasius R, Buck I, Dicato M, Diederich M. Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. *Cancer Lett* 2006;240:203-12.
- [78] Buck I, Morceau F, Cristofanon S, Heintz C, Chateauvieux S, Reuter S, et al. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation. *Biochem Pharmacol* 2008;76:1229-39.
- [79] Buck I, Morceau F, Cristofanon S, Reuter S, Dicato M, Diederich M. The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation. *Int J Oncol* *In press*.
- [80] Miwatashi S, Arikawa Y, Kotani E, Miyamoto M, Naruo K, Kimura H, et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide


- (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. *J Med Chem* 2005;48:5966-79.
- [81] Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. *Curr Opin Hematol* 2002;9:93-100.
- [82] Tsai FY, Orkin SH. Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. *Blood* 1997;89:3636-43.
- [83] Shivdasani RA, Orkin SH. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. *Proc Natl Acad Sci U S A* 1995;92:8690-4.
- [84] Tsang AP, Visvader JE, Turner CA, Fujiwara Y, Yu C, Weiss MJ, et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. *Cell* 1997;90:109-19.
- [85] Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. *Embo J* 1997;16:3145-57.
- [86] Blobel GA, Nakajima T, Eckner R, Montminy M, Orkin SH. CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. *Proc Natl Acad Sci U S A* 1998;95:2061-6.
- [87] Gregory RC, Taxman DJ, Seshasayee D, Kensinger MH, Bieker JJ, Wojchowski DM. Functional interaction of GATA1 with erythroid Kruppel-like factor and Sp1 at defined erythroid promoters. *Blood* 1996;87:1793-801.
- [88] Matsumura I, Kawasaki A, Tanaka H, Sonoyama J, Ezoe S, Minegishi N, et al. Biologic significance of GATA-1 activities in Ras-mediated megakaryocytic differentiation of hematopoietic cell lines. *Blood* 2000;96:2440-50.

Buck et al, Figure 1



trip

Buck et al, Figure 2



Buck et al, Figure 3




Table 1: The main transcription factors and co-factors involved in the regulation of erythroid specific genes expression and their positive (+) or negative (-) effect on erythropoiesis.

| Factor name | Effect | References |
|--------------------------------------|---------------|-------------------|
| GATA-1 | + | [20] |
| GATA-2 | +/- | [82] |
| NF-E2 (Nuclear Factor Erythroid 2) | + | [83] |
| FOG (Friend of GATA) -1 | + | [84] |
| Lmo2 (LIM-only protein 2) (Rbtn2) | + | [85] |
| p300/CBP | + | [86] |
| EKLF (Erythroid Kruppel like factor) | + | [87] |
| PU.1 (SPI1) | - | [22] |
| c-myb | . | [88] |